Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

NCT06764875 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06764875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06764875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
March 1, 2025
Completion date
December 9, 2030
Enrollment
840 (estimated)
Sites
302

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal junction adenocarcinoma, her2-positive gastric cancer